Jeff Nippard On Peptides.
A coach reacts to a Jeff Nippard video on peptides, covering GLP-1 weight loss drugs, dosing and side effects, and the thin human evidence for BPC-157 and TB-500.
With Jeff Nippard (degree in biochemistry (self-described in the clip))
Key moments
Tap a moment to play the video from there.
- 0:00Peptide categories and usesDoucette introduces Nippard's three categories of weight loss, anti-aging and repair, and lists other uses he thinks were left out, such as muscle growth and sleep.
- 1:31Nippard's credentials and disclosureA clip has Nippard stating his background and that he takes no peptide sponsorship. Doucette then discloses he is part owner of Algo RX and explains its product line.
- 2:32Semaglutide and how it worksDoucette says semaglutide clearly works, describing blood sugar control, slower stomach emptying and less hunger. He says to use the lowest dose that makes you happy.
- 4:042018 trial and who should use GLPsHe cites a 2018 trial with 34 lbs lost versus 6 lbs on placebo. He says people who have repeatedly failed to lose weight should talk to their doctor.
- 5:36Starting doses are too highDoucette says doctors often start patients on doses he considers too high and that clients should ask for the lowest dose and titrate slowly.
- 6:38Newer drugs and starting smallHe compares semaglutide's 15% weight loss with tirzepatide at 23% and retatrutide at 28%, and says retatrutide is not yet approved.
- 8:42Safety versus obesity and surgeryDoucette argues obesity is itself unsafe and that a weekly injection is a safer option than gastric bypass for those considering surgery.
- 11:48Muscle loss and the shortcut debateHe says up to 40% of weight lost can be lean tissue, so lifting and diet still matter. He then defends calling the drugs a shortcut.
- 14:51BPC-157 and TB-500 evidenceA clip says the evidence for BPC-157 is preclinical. Doucette says millions use the Wolverine stack and that he thinks BPC-157 works.
- 17:25Human research gapDoucette says that going by human research alone, people cannot be advised to use BPC-157, though he does not tell viewers to avoid it.
What the video says
This is a reaction video. Greg Doucette plays clips from a Jeff Nippard peptide video and talks over them. The clips and Doucette's commentary are mixed together, and the video also contains promotion for products Doucette has a stake in. Doucette says Nippard sorts peptides into weight loss, anti-aging and repair, and adds that peptides are also discussed for muscle growth, sleep, sexual health, stress and endurance.
Most of the runtime goes to GLP-1 fat loss drugs. Doucette says semaglutide clearly works, and cites a 2018 trial in which the treated group lost 34 lbs in 16 months against 6 lbs for placebo. He says newer drugs go further, with tirzepatide at 23% weight loss against semaglutide's 15%, and retatrutide at 28% after phase three trials. He argues people should start with the cheaper, older drug at the lowest dose that satisfies them, and he is critical of doctors who start patients on higher doses. He says higher doses bring more nausea, vomiting, constipation and diarrhea, and he describes clients being hospitalized.
Doucette also compares GLP-1 use with gastric bypass surgery and says he sees the drug as the safer option for people who qualify. He repeats a figure from the clips that up to 40% of weight lost can be lean tissue, and says lifting, cardio and diet still matter. He defends calling the drugs a shortcut, saying there is nothing wrong with that. He says they suit people who struggle with hunger, not those already lean who want to get leaner.
The last section covers BPC-157 and TB-500, the so-called Wolverine stack. A clip says the research is preclinical, not in humans. Doucette agrees the human evidence is weak but says he has used BPC-157 and thinks it works, and he leans on user reports. He compares this to a supplement he sells. Doucette says his own company's peptide line does not include BPC-157.
On each compound
Semaglutide2:32
Doucette says semaglutide clearly works and cites a 2018 trial with 34 lbs lost against 6 lbs on placebo. He says to start at the lowest dose that makes you happy, because high doses can cause nausea and vomiting.
See how your DNA reads SemaglutideTirzepatide6:38
Doucette says tirzepatide caused 23% weight loss in a similar time frame, against 15% for semaglutide. He argues people should still start with the older drug and move up only if they stall.
See how your DNA reads TirzepatideRetatrutide6:38
Doucette says retatrutide passed phase three trials with 28% weight loss but is not yet approved. He says people using it are guinea pigs and claims it has the worst side effects and dropout rate.
See how your DNA reads RetatrutideBPC-15715:21
Doucette says he has used BPC-157 and thinks it works, though he concedes the human evidence is lacking. A clip he plays says the supporting studies were preclinical, and he says his own company's product line does not include it.
See how your DNA reads BPC-157TB-50015:21
Doucette groups TB-500 with BPC-157 as the Wolverine stack and says many people swear by it. He says the research is not really there, but that this does not mean it fails to work.
See how your DNA reads TB-500“The peptides essentially all they do is they make you eat less.”
“Of course it's a shortcut. What's wrong with taking a shortcut?”
What this video doesn’t settle
- The 40% lean mass figure is presented in a clip without a named source or study.
- Doucette's claims about doctors overprescribing and insurance driving higher doses come from his own observation and are not backed by data in the video.
- The case for BPC-157 and TB-500 rests on personal experience and user reports, with no human trial presented.
Questions this video answers
What does Greg Doucette say about starting dose for semaglutide and tirzepatide?
Doucette says doctors often start patients on too high a dose. He thinks 2.5 milligrams should be a maximum starting dose, not a minimum, and says patients should ask for the lowest dose and raise it slowly.
How much weight loss do semaglutide, tirzepatide and retatrutide produce according to this video?
Doucette gives about 15% for semaglutide, 23% for tirzepatide and 28% for retatrutide. He says retatrutide has finished phase three trials but is not yet approved.
Do GLP-1 drugs cause muscle loss?
Doucette repeats a figure from the clips that up to 40% of the weight lost can be lean tissue. He says lifting weights, cardio and a healthy diet are still needed alongside the drug.
Does the video say BPC-157 and TB-500 work?
Doucette says he thinks BPC-157 works from personal use and from clients. He agrees the human research is not strong enough to advise it, and a clip says the existing studies were preclinical.
Is this video a neutral review of peptides?
Not entirely. Doucette says he is part owner of Algo RX and promotes his own products and discount codes during the video.
Video by Greg Doucette on YouTube, embedded as published. The summary is written by PeptidesDNA from the video; every claim in it is the speaker’s. Not affiliated with or endorsed by the creator. Not medical advice.
